Hospital
ST Joseph's Children Hospital
ST Joseph's Children Hospital was paid $5.98M by Medicaid between Jan 2018 and Aug 2022, across 96 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoST JOSEPH'S CHILDREN HOSPITAL
PATERSON, NJ 07503
PATERSON, NJ 07503
33aNPI1285867705assigned 09/01/2009
33bProvider typeChildren's Hospital
28Total paid$5.98M
24GClaims78,189
24DCodes billed96
24AFirst – last monthJan 2018 – Aug 2022
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,072 | $998K | |
| 2019 | 10,001 | $776K | |
| 2020 | 15,359 | $1.20M | |
| 2021 | 24,657 | $1.88M | |
| 2022 | 16,100 | $1.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 4,226 | 3,818 | $1.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 4,823 | 4,526 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 1,414 | 1,319 | $805K |
| OP272 | 3.7% | 842 | 816 | $221K | |
| OP710 | 3.5% | 427 | 416 | $210K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.4% | 2,514 | 2,270 | $204K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 846 | 811 | $156K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 2,972 | 2,765 | $138K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 1,593 | 1,479 | $116K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 1,568 | 1,325 | $116K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.9% | 1,679 | 1,388 | $115K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 313 | 290 | $105K |
84 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 952 | $100K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 1,111 | $92K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 4,806 | $91K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.5% | 217 | $87K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 212 | $85K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 483 | $80K |
| OP250 | 1.2% | 8,166 | $70K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 577 | $48K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,854 | $47K |
| 80053 | Comprehensive metabolic panel | <1% | 4,287 | $43K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,490 | $40K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 265 | $37K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,247 | $34K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 92 | $32K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 321 | $31K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 231 | $31K |
| 86900 | <1% | 1,290 | $30K | |
| 86850 | <1% | 1,116 | $27K | |
| 86901 | <1% | 1,289 | $26K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 128 | $15K |
| 84484 | <1% | 978 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 58 | $10K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 28 | $9K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 902 | $9K |
| 81025 | <1% | 2,612 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 818 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 268 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 259 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 809 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 85 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 75 | $5K |
| 93017 | <1% | 28 | $5K | |
| 82962 | <1% | 1,098 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 662 | $4K |
| 85027 | <1% | 736 | $4K | |
| OP258 | <1% | 604 | $4K | |
| 88342 | <1% | 37 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 23 | $3K |
| 83690 | <1% | 716 | $3K | |
| 85610 | <1% | 1,116 | $3K | |
| 81001 | <1% | 2,548 | $3K | |
| 83735 | <1% | 681 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 65 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,430 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 27 | $2K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 212 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 29 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,459 | $2K |
| 84702 | <1% | 167 | $2K | |
| 90686 | <1% | 328 | $1K | |
| 59025 | Fetal non-stress test | <1% | 13 | $1K |
| 85730 | <1% | 663 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,186 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 541 | $1K |
| 81003 | <1% | 553 | $840.94 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 105 | $814.24 |
| 84100 | <1% | 250 | $782.20 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 25 | $765.78 |
| 73610 | <1% | 14 | $716.79 | |
| 80061 | Lipid panel | <1% | 45 | $710.50 |
| J3490 | Unclassified drugs | <1% | 526 | $689.54 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 53 | $673.20 |
| A4649 | Surgical supply; miscellaneous | <1% | 108 | $632.93 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 599 | $623.92 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 12 | $515.68 |
| 87522 | Neg quan hep c or qual rna | <1% | 25 | $470.72 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 28 | $457.94 |
| 87070 | <1% | 47 | $443.54 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 363 | $389.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 391 | $356.18 |
| 82077 | <1% | 29 | $288.77 | |
| 90715 | <1% | 13 | $281.43 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 73 | $275.44 |
| 80076 | <1% | 28 | $201.25 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 26 | $167.98 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 41 | $102.10 |
| A0425 | Ground mileage, per statute mile | <1% | 12 | $101.40 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 86 | $69.27 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 14 | $37.16 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 34 | $34.85 |
| 90633 | 0% | 13 | $0.00 | |
| 90670 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDALEY, THOMAS (PROGRAM DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Great Lakes Orthopedic Labs, INC | Buffalo, NY | $245K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.